Abstract
Varenicline tartrate (Chantix; Pfizer), an α4β2 nicotinic receptor partial agonist, was approved by the US FDA as an aid to smoking cessation treatment in May 2006.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Ezzati, M. et al. Estimates of global mortality attributable to smoking in 2000. Lancet 362, 847–852 (2003).
Henningfield, J. E. et al. Pharmacotherapy for nicotine dependence. CA Cancer J. Clin. 55, 281–299 (2005).
Dani, J. A. & Heinemann, S. Molecular and cellular aspects of nicotine abuse. Neuron 16, 905–908 (1996).
Picciotto, M. R. et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173–177 (1998).
Tapper, A. R. et al. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306, 1029–1032 (2004).
Coe, J. W. et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48, 3474–3477 (2005).
FDA labelling information, [online] (2006).
Piper, M. E. et al. A multiple motives approach to tobacco dependence: the Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). J. Consult. Clin. Psychol. 72, 139–154 (2004).
Lancaster, T. et al. Prevention of relapse after quitting smoking: a systematic review of trials. Arch. Intern. Med. 166, 828–835 (2006).
Grant, B. F. et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry 61, 1107–1115 (2004).
Mackay, J. & Eriksen, M. The Tobacco Atlas. World Health Organization, [online] (2004).
IMS Health, IMS MIDAS Quantum (Dec 2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niaura, R., Jones, C. & Kirkpatrick, P. Varenicline. Nat Rev Drug Discov 5, 537–538 (2006). https://doi.org/10.1038/nrd2088
Issue date:
DOI: https://doi.org/10.1038/nrd2088
This article is cited by
-
Increased interregional functional connectivity of anterior insula is associated with improved smoking cessation outcome
Brain Imaging and Behavior (2020)
-
New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?
CNS Drugs (2016)
-
Nephrotoxic effects of varenicline as the most effective drug used for smoking cessation: a preliminary experimental study
International Urology and Nephrology (2015)
-
Single dose varenicline may trigger epileptic activity
Neurological Sciences (2014)
-
Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control
Psychopharmacology (2011)
